Copyright Reports & Markets. All rights reserved.

Global Pulmonary Arterial Hypertension (PAH) Market Research Report 2019

Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Pulmonary Arterial Hypertension (PAH) Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Prostacyclin and Prostacyclin Analogs
    • 1.4.3 SGC Stimulators
    • 1.4.4 ERA
    • 1.4.5 PDE-5
  • 1.5 Market by Application
    • 1.5.1 Global Pulmonary Arterial Hypertension (PAH) Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Clinic
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Pulmonary Arterial Hypertension (PAH) Market Perspective (2015-2026)
  • 2.2 Global Pulmonary Arterial Hypertension (PAH) Growth Trends by Regions
    • 2.2.1 Pulmonary Arterial Hypertension (PAH) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Pulmonary Arterial Hypertension (PAH) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Pulmonary Arterial Hypertension (PAH) Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Pulmonary Arterial Hypertension (PAH) Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Market Size
    • 3.1.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue (2015-2020)
    • 3.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Pulmonary Arterial Hypertension (PAH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio
    • 3.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Revenue in 2019
  • 3.3 Pulmonary Arterial Hypertension (PAH) Key Players Head office and Area Served
  • 3.4 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
  • 3.5 Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2015-2020)
  • 4.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)
  • 5.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
  • 6.2 Pulmonary Arterial Hypertension (PAH) Key Players in North America (2019-2020)
  • 6.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
  • 6.4 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
  • 7.2 Pulmonary Arterial Hypertension (PAH) Key Players in Europe (2019-2020)
  • 7.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
  • 7.4 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

8 China

  • 8.1 China Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
  • 8.2 Pulmonary Arterial Hypertension (PAH) Key Players in China (2019-2020)
  • 8.3 China Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
  • 8.4 China Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
  • 9.2 Pulmonary Arterial Hypertension (PAH) Key Players in Japan (2019-2020)
  • 9.3 Japan Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
  • 9.4 Japan Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
  • 10.2 Pulmonary Arterial Hypertension (PAH) Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

11 India

  • 11.1 India Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
  • 11.2 Pulmonary Arterial Hypertension (PAH) Key Players in India (2019-2020)
  • 11.3 India Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
  • 11.4 India Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
  • 12.2 Pulmonary Arterial Hypertension (PAH) Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
  • 12.4 Central & South America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Actelion
    • 13.1.1 Actelion Company Details
    • 13.1.2 Actelion Business Overview
    • 13.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Introduction
    • 13.1.4 Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020))
    • 13.1.5 Actelion Recent Development
  • 13.2 Gilead Sciences
    • 13.2.1 Gilead Sciences Company Details
    • 13.2.2 Gilead Sciences Business Overview
    • 13.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Introduction
    • 13.2.4 Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
    • 13.2.5 Gilead Sciences Recent Development
  • 13.3 United Therapeutics
    • 13.3.1 United Therapeutics Company Details
    • 13.3.2 United Therapeutics Business Overview
    • 13.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Introduction
    • 13.3.4 United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
    • 13.3.5 United Therapeutics Recent Development
  • 13.4 GlaxoSmithKline
    • 13.4.1 GlaxoSmithKline Company Details
    • 13.4.2 GlaxoSmithKline Business Overview
    • 13.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Introduction
    • 13.4.4 GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
    • 13.4.5 GlaxoSmithKline Recent Development
  • 13.5 Pfizer
    • 13.5.1 Pfizer Company Details
    • 13.5.2 Pfizer Business Overview
    • 13.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Introduction
    • 13.5.4 Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
    • 13.5.5 Pfizer Recent Development
  • 13.6 Bayer
    • 13.6.1 Bayer Company Details
    • 13.6.2 Bayer Business Overview
    • 13.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Introduction
    • 13.6.4 Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
    • 13.6.5 Bayer Recent Development
  • 13.7 Arena
    • 13.7.1 Arena Company Details
    • 13.7.2 Arena Business Overview
    • 13.7.3 Arena Pulmonary Arterial Hypertension (PAH) Introduction
    • 13.7.4 Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
    • 13.7.5 Arena Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Pulmonary Arterial Hypertension (PAH) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Pulmonary Arterial Hypertension (PAH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Actelion
    Gilead Sciences
    United Therapeutics
    GlaxoSmithKline
    Pfizer
    Bayer
    Arena
    ...

    Market segment by Type, the product can be split into
    Prostacyclin and Prostacyclin Analogs
    SGC Stimulators
    ERA
    PDE-5
    Market segment by Application, split into
    Hospital
    Clinic

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now